Lens Extraction Combined With Goniosynechialysis Versus Trabeculectomy

Sponsor
Eye & ENT Hospital of Fudan University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04703712
Collaborator
(none)
316
2
47

Study Details

Study Description

Brief Summary

To compare the effectiveness of lens extraction combined with goniosynechialysis and trabeculectomy in treating advanced angle-closure glaucoma.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Lens extraction combined with goniosynechialysis
  • Procedure: Trabeculectomy surgery
N/A

Detailed Description

Advanced angle closure glaucoma (AACG) can result in severe visual function defect or even blindness with or without acute attacks. Different from open angle glaucoma (OAG), the main principle of treatment for AACG is not only to lower intraocular pressure (IOP) but also to protect the anterior chamber angle from closing. Previously, the most common and classical treatment for AACG was trabeculectomy. However, both doctors and patients are not satisfied with this surgery because of its limited success rate due to fibrosis of the filtration pathway. Besides, trabeculectomy has various complications, such as shallow anterior chamber, choroidal effusion, suprachoroidal hemorrhage, malignant glaucoma, and bleb leakage associated endophthalmitis. In addition, patients who underwent trabeculectomy will have decreased visual acuity in a couple of years due to accelerated development of cataract. Since a thickened and anterior-positioned lens could play a crucial role in the pathogenesis of AACG, cataract surgery has also been used. Accumulative evidence shows lens extraction alone is an efficient way in treating the early stage of ACG but has limited success rate in AACG. Lens extraction combined with goniosynechialysis (LEG) has been proved to be better than lens extraction alone in re-opening the anterior chamber angle for ACG patients with extensive peripheral anterior synechia and possibly have better effect than trabeculectomy as well from our preliminary data, which has not been proved yet. Thus, this investigation is designed to compare the effect of LEG and trabeculectomy in AACG patients prospectively in 3 years of follow-up. The investigators hypothesize that LEG could have better IOP control and better visual function than trabeculectomy in long term for AACG patients.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
316 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Lens Extraction Combined With Goniosynechialysis Versus Trabeculectomy in Treating Advanced Angle-closure Glaucoma: a Randomized Controlled Trial
Anticipated Study Start Date :
Jan 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Lens extraction combined with goniosynechialysis group

One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent phacoemulsification combined with goniosynechialysis.

Procedure: Lens extraction combined with goniosynechialysis
The patients enrolled underwent phacoemulsification combined with goniosynechialysis surgery.

Active Comparator: Trabeculectomy Group

One hundred and fifty-eight patients with advanced angle-closure glaucoma underwent trabeculectomy.

Procedure: Trabeculectomy surgery
The patients enrolled underwent trabeculectomy surgery

Outcome Measures

Primary Outcome Measures

  1. Intraocular pressure (IOP) change at one month [one month]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at one month.

  2. IOP change at three months [three months]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at three months.

  3. IOP change at six months [six months]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at six months.

  4. IOP change at one year [one year]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at one year.

  5. IOP change at two years [two years]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at two years.

  6. IOP change at three years [three years]

    Change from baseline IOP after phacoemulsification combined with goniosynechialysis or trabeculectomy at three years.

  7. Best corrected visual acuity at one month [one month]

    Best corrected visual acuity of participants after surgery at one month

  8. Best corrected visual acuity at three months [three months]

    Best corrected visual acuity of participants after surgery at three months

  9. Best corrected visual acuity at six months [six months]

    Best corrected visual acuity of participants after surgery at six months

  10. Best corrected visual acuity at one year [one year]

    Best corrected visual acuity of participants after surgery at one year

  11. Best corrected visual acuity at two years [two years]

    Best corrected visual acuity of participants after surgery at two years

  12. Best corrected visual acuity at three years [three years]

    Best corrected visual acuity of participants after surgery at three years

Secondary Outcome Measures

  1. Mean deviation [one month, three months, six months, one year, two years, three years]

    The mean deviation value of Humphery visual filed tests before and after surgery.

  2. The thickness of retinal nerve fiber layer (RNFL) [one month, three months, six months, one year, two years, three years]

    The RNFL thickness measured by optical coherence topography (OCT)

  3. The thickness of ganglion cell complex (GCC) [one month, three months, six months, one year, two years, three years]

    The GCC thickness measured by OCT

  4. Number of eye drops [one month, three months, six months, one year, two years, three years]

    The number of eye drops after surgery.

  5. Adverse event [one month, three months, six months, one year, two years, three years]

    Adverse events of each group, such as cornea edma, ocular hypotension, hemorrhage

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Age between 40 years old to 80 years old

  2. more than 180-degree synechial closure of anterior chamber angle on gonioscopy

  3. IOP higher than 21mmHg under the use of more than two anti-glaucoma eye drops

  4. mean deviation of visual field worse than -12dB on Humphrey 24-2

  5. phakic eyes

Exclusion Criteria:
  1. Snellen visual acuity worse than 0.02

  2. history of ocular trauma

  3. uveitis

  4. previous ocular surgeries

  5. significant conjunctival scar

  6. visible neovascular on iris or anterior chamber angle

  7. other severe eye diseases that would affect visual function significantly, such as age-related macular degeneration and pathogenic myopia.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Eye & ENT Hospital of Fudan University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yuhong Chen, Professor, Eye & ENT Hospital of Fudan University
ClinicalTrials.gov Identifier:
NCT04703712
Other Study ID Numbers:
  • AAC Glaucoma
First Posted:
Jan 11, 2021
Last Update Posted:
Jan 11, 2021
Last Verified:
Jan 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yuhong Chen, Professor, Eye & ENT Hospital of Fudan University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2021